Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study

AIMS: Tafamidis is an effective treatment for transthyretin amyloid cardiomyopathy (ATTR‐CM) in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT). While ATTR‐ACT was not designed for a dose‐specific assessment, further analysis from ATTR‐ACT and its long‐term extension study (L...

Descripción completa

Detalles Bibliográficos
Autores principales: Damy, Thibaud, Garcia‐Pavia, Pablo, Hanna, Mazen, Judge, Daniel P., Merlini, Giampaolo, Gundapaneni, Balarama, Patterson, Terrell A., Riley, Steven, Schwartz, Jeffrey H., Sultan, Marla B., Witteles, Ronald
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2020
Materias:
Focus on Myocarditis, Cardiomyopathy and Amyloidosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048553/
https://www.ncbi.nlm.nih.gov/pubmed/33070419
http://dx.doi.org/10.1002/ejhf.2027

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048553/
https://www.ncbi.nlm.nih.gov/pubmed/33070419
http://dx.doi.org/10.1002/ejhf.2027

Ejemplares similares